These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 27228981)

  • 21. Economic considerations in a changing anemia environment.
    Pizzi LT
    Am J Kidney Dis; 2008 Dec; 52(6 Suppl):S29-33. PubMed ID: 19010259
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bundled payment for ESRD--including ESAs in Medicare's dialysis package.
    Iglehart JK
    N Engl J Med; 2011 Feb; 364(7):593-5. PubMed ID: 21323538
    [No Abstract]   [Full Text] [Related]  

  • 23. Managing oral phosphate binder medication expenditures within the Medicare bundled end-stage renal disease prospective payment system: economic implications for large U.S. dialysis organizations.
    Park H; Rascati KL; Keith MS
    J Manag Care Spec Pharm; 2015 Jun; 21(6):507-14. PubMed ID: 26011552
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Costs of managing anemia with erythropoiesis-stimulating agents during hemodialysis: a time and motion study.
    Schiller B; Doss S; DE Cock E; Del Aguila MA; Nissenson AR
    Hemodial Int; 2008 Oct; 12(4):441-9. PubMed ID: 19090867
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bundled-rate legislation for Medicare reimbursement for dialysis services: implications for anemia management with ESAs.
    Charytan C
    Clin J Am Soc Nephrol; 2010 Dec; 5(12):2355-62. PubMed ID: 21071515
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Economic and quality of life burden of anemia on patients with CKD on dialysis: a systematic review.
    Spinowitz B; Pecoits-Filho R; Winkelmayer WC; Pergola PE; Rochette S; Thompson-Leduc P; Lefebvre P; Shafai G; Bozas A; Sanon M; Krasa HB
    J Med Econ; 2019 Jun; 22(6):593-604. PubMed ID: 30813807
    [No Abstract]   [Full Text] [Related]  

  • 27. Using race as a case-mix adjustment factor in a renal dialysis payment system: potential and pitfalls.
    Roach JL; Turenne MN; Hirth RA; Wheeler JR; Sleeman KS; Messana JM
    Am J Kidney Dis; 2010 Nov; 56(5):928-36. PubMed ID: 20888100
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of capitation on free-standing dialysis facilities: can you survive?
    McMurray SD; Miller J
    Am J Kidney Dis; 1997 Oct; 30(4):542-8. PubMed ID: 9328370
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Historical clinical and economic consequences of anemia management in patients with end-stage renal disease on dialysis using erythropoietin stimulating agents versus routine blood transfusions: a retrospective cost-effectiveness analysis.
    Naci H; de Lissovoy G; Hollenbeak C; Custer B; Hofmann A; McClellan W; Gitlin M
    J Med Econ; 2012; 15(2):293-304. PubMed ID: 22115328
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anemia management trends in hospital-based dialysis centers (HBDCs), 2010 to 2013.
    Coritsidis GN; Maglinte GA; Acharya A; Saxena A; Chang CL; Hill J; Gitlin M; Lafayette RA
    Clin Ther; 2014 Mar; 36(3):408-18. PubMed ID: 24582713
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
    Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
    Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost implications to Medicare of recombinant erythropoietin therapy for the anemia of end-stage renal disease.
    Powe NR; Griffiths RI; Bass EB
    J Am Soc Nephrol; 1993 Apr; 3(10):1660-71. PubMed ID: 8318682
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Incremental cost effectiveness of pharmacist-managed erythropoiesis-stimulating agent clinics for non-dialysis-dependent chronic kidney disease patients.
    Aspinall SL; Smith KJ; Good CB; Zhao X; Stone RA; Tonnu-Mihara IQ; Cunningham FE
    Appl Health Econ Health Policy; 2013 Dec; 11(6):653-60. PubMed ID: 24092553
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dialysis facility ownership and epoetin dosing in patients receiving hemodialysis.
    Thamer M; Zhang Y; Kaufman J; Cotter D; Dong F; Hernán MA
    JAMA; 2007 Apr; 297(15):1667-74. PubMed ID: 17440144
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative mortality risk of anemia management practices in incident hemodialysis patients.
    Brookhart MA; Schneeweiss S; Avorn J; Bradbury BD; Liu J; Winkelmayer WC
    JAMA; 2010 Mar; 303(9):857-64. PubMed ID: 20197532
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characterizing hospitalizations of end-stage renal disease patients on dialysis and inpatient utilization of erythropoiesis-stimulating agent therapy.
    Brophy DF; Daniel G; Gitlin M; Mayne TJ
    Ann Pharmacother; 2010 Jan; 44(1):43-9. PubMed ID: 20028955
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Medicare Program; End-Stage Renal Disease Prospective Payment System, Payment for Renal Dialysis Services Furnished to Individuals With Acute Kidney Injury, and End-Stage Renal Disease Quality Incentive Program. Final rule.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2017 Nov; 82(210):50738-97. PubMed ID: 29091373
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Medicare payment policy and recombinant erythropoietin prescribing for dialysis patients.
    Powe NR; Griffiths RI; Anderson GF; de Lissovoy G; Watson AJ; Greer JW; Herbert RJ; Whelton PK
    Am J Kidney Dis; 1993 Oct; 22(4):557-67. PubMed ID: 8213796
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The clinical and economic burden of pneumonia in patients enrolled in Medicare receiving dialysis: a retrospective, observational cohort study.
    Sibbel S; Sato R; Hunt A; Turenne W; Brunelli SM
    BMC Nephrol; 2016 Dec; 17(1):199. PubMed ID: 27955633
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Projected impact of the proposed "bundled" ESRD payment system on a small dialysis organization.
    Bhat P; Sokolowski W; Bhat JG
    Nephrol News Issues; 2009 Jun; 23(7):46, 48-52. PubMed ID: 19585810
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.